Update: State Disclosure and Transparency Laws for Pharmaceutical and Medical Device Manufacturers - McGuireWoods
State has updated disclosure and transparency laws for pharmaceutical and medical device manufacturers; compliance requirements may have changed.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 3, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical and medical device manufacturers operating in the state. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the update.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Updates to disclosure and transparency laws that may affect reporting and compliance obligations.
Who it affects
All pharmaceutical and medical device manufacturers operating in the state.
What you must do
Review the updated laws to ensure compliance with any new disclosure requirements.
Deadline
Not specified in the update.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- DEA Announces New Marijuana Registration Forms For Manufacturing, Distribution And Testing Businesses - Marijuana Moment
- CDER’s Framework for Regulatory Advanced Manufacturing Evaluation (FRA - fda.gov
- Determination That PHENAPHEN WITH CODEINE NO. 3 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 30 Milligrams, and PHENAPHEN WITH CODEINE NO. 4 (Acetaminophen; Codeine Phosphate) Oral Capsules, 325 Milligrams and 60 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Novartis, AbbVie Score Win to Block West Virginia Drug Limit Law - news.bloomberglaw.com
- FDA Tightens the Belt on GLP-1 Compounding, Escalating Threat of Enforcement - natlawreview.com